Markus Hosang is a General Partner of BioMedPartners AG, Basel Switzerland, a major investor in Anergis. Beforehand, Dr. Hosang was Venture Partner at MPM Capital, where he was co-responsible for the European deal flow, managed the European office in Munich, and served on the board of several portfolio companies. Prior to joining MPM in 2002, Dr Hosang served for nearly 20 years at Hoffmann-La Roche in several senior management positions in the Pharma R&D organization, including VP and Director of the International Pharma Research Strategy Unit and Chief of Staff to the President of Roche Global R&D. He served on the Global Board of R&D Directors and the Pharma Portfolio Board. In his last position at Roche, he was VP and CSO of Genetics and Integrated Medicine and a member of the Roche Genetics Executive Committee. He also served as a member of the Board and as a Trustee of the Swiss Foundation for Stipends in Biology and Medicine for many years. Dr Hosang received his Ph.D. degree in Biochemistry from the ETH in Zurich, and pursued postgraduate fellowships at Stanford University Medical School and at the University of Washington Medical School in Seattle.

 Biology and Medicine